Skip to main content
Top
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2016 | Research article

Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study

Authors: Licia Grazzi, Gabriella Egeo, Anne H. Calhoun, Candace K. McClure, Eric Liebler, Piero Barbanti

Published in: The Journal of Headache and Pain | Issue 1/2015

Login to get access

Abstract

Background

Menstrual migraine and menstrually related migraine attacks are typically longer, more disabling, and less responsive to medications than non-menstrual attacks. The aim of this study was to evaluate the efficacy, safety, and tolerability of non-invasive vagus nerve stimulation for the prophylactic treatment of menstrual migraine/menstrually related migraine.

Methods

Fifty-six enrolled subjects (menstrual migraine, 9 %; menstrually related migraine, 91 %), 33 (59 %) of whom were receiving other prophylactic therapies, entered a 12-week baseline period. Fifty-one subjects subsequently entered a 12-week treatment period to receive open-label prophylactic non-invasive vagus nerve stimulation adjunctively (31/51; 61 %) or as monotherapy (20/51; 39 %) on day −3 before estimated onset of menses through day +3 after the end of menses.

Results

The number of menstrual migraine/menstrually related migraine days per month was significantly reduced from baseline (mean ± standard error, 7.2 ± 0.7 days) to the end of treatment (mean ± standard error, 4.7 ± 0.5 days; P < 0.001) (primary end point). Of all subjects, 39 % (95 % confidence interval: 26 %, 54 %) (20/51) had a ≥ 50 % reduction (secondary end point). For the other secondary end points, clinically meaningful reductions in analgesic use (mean change ± standard error, −3.3 ± 0.6 times per month; P < 0.001), 6-item Headache Impact Test score (mean change ± standard error, −3.1 ± 0.7; P < 0.001), and Migraine Disability Assessment score (mean change ± standard error, −11.9 ± 3.4; P < 0.001) were observed, along with a modest reduction in pain intensity (mean change ± standard error, −0.5 ± 0.2; P = 0.002). There were no safety/tolerability concerns.

Conclusions

These findings suggest that non-invasive vagus nerve stimulation is an effective treatment that reduces the number of menstrual migraine/menstrually related migraine days and analgesic use without safety/tolerability concerns in subjects with menstrual migraine/menstrually related migraine. Randomised controlled studies are warranted.
Literature
1.
go back to reference Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.1177/0333102413485658 CrossRef Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.​1177/​0333102413485658​ CrossRef
8.
go back to reference Silberstein SD (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754–762CrossRefPubMed Silberstein SD (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754–762CrossRefPubMed
12.
go back to reference Adelman JU, Calhoun A (2005) A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 64:931, author replyCrossRefPubMed Adelman JU, Calhoun A (2005) A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 64:931, author replyCrossRefPubMed
13.
go back to reference Calhoun A, Ford S (2008) Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache 48:1186–1193CrossRefPubMed Calhoun A, Ford S (2008) Elimination of menstrual-related migraine beneficially impacts chronification and medication overuse. Headache 48:1186–1193CrossRefPubMed
17.
go back to reference Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A, on behalf of the PREVA Study Group (2016) Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia 36:534–546. doi:10.1177/0333102415607070 CrossRefPubMed Gaul C, Diener HC, Silver N, Magis D, Reuter U, Andersson A, Liebler EJ, Straube A, on behalf of the PREVA Study Group (2016) Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. Cephalalgia 36:534–546. doi:10.​1177/​0333102415607070​ CrossRefPubMed
19.
go back to reference Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H (2015) Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain 16:101. doi:10.1186/s10194-015-0582-9 CrossRefPubMedPubMedCentral Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H (2015) Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. J Headache Pain 16:101. doi:10.​1186/​s10194-015-0582-9 CrossRefPubMedPubMedCentral
20.
go back to reference Barbanti P, Aurilia C, Dall’Armi V, Egeo G, Fofi L, Bonassi S (2016) The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia. doi:10.1177/0333102416630579. Barbanti P, Aurilia C, Dall’Armi V, Egeo G, Fofi L, Bonassi S (2016) The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia. doi:10.​1177/​0333102416630579​.
22.
go back to reference Stewart WF, Lipton RB, Kolodner K (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43:258–265CrossRefPubMed Stewart WF, Lipton RB, Kolodner K (2003) Migraine disability assessment (MIDAS) score: relation to headache frequency, pain intensity, and headache symptoms. Headache 43:258–265CrossRefPubMed
23.
31.
go back to reference Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR (2013) Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. Cephalalgia 33:340–346. doi:10.1177/0333102412473373 CrossRefPubMed Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR (2013) Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. Cephalalgia 33:340–346. doi:10.​1177/​0333102412473373​ CrossRefPubMed
32.
go back to reference Coffee AL, Sulak PJ, Hill AJ, Hansen DJ, Kuehl TJ, Clark JW (2014) Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt) 23:310–317. doi:10.1089/jwh.2013.4485 CrossRef Coffee AL, Sulak PJ, Hill AJ, Hansen DJ, Kuehl TJ, Clark JW (2014) Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines. J Womens Health (Larchmt) 23:310–317. doi:10.​1089/​jwh.​2013.​4485 CrossRef
34.
go back to reference Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW (2007) Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 47:1037–1049. doi:10.1111/j.1526-4610.2007.00855.x CrossRefPubMed Mannix LK, Savani N, Landy S, Valade D, Shackelford S, Ames MH, Jones MW (2007) Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 47:1037–1049. doi:10.​1111/​j.​1526-4610.​2007.​00855.​x CrossRefPubMed
35.
go back to reference Calhoun AH, Pruitt AP (2015) Presenting a new, non-hormonally mediated menstrual headache: end-menstrual migraine [AHS abstract PS18]. Headache 55(suppl 3):127–187 Calhoun AH, Pruitt AP (2015) Presenting a new, non-hormonally mediated menstrual headache: end-menstrual migraine [AHS abstract PS18]. Headache 55(suppl 3):127–187
36.
38.
go back to reference Rainero I, De Martino P, Rubino E, Vaula G, Gentile S, Pinessi L (2014) Non-invasive vagal nerve stimulation for the treatment of headache attacks in patients with chronic migraine and medication-overuse headache [AAN abstract]. Neurology 82(suppl 10):P1.262 Rainero I, De Martino P, Rubino E, Vaula G, Gentile S, Pinessi L (2014) Non-invasive vagal nerve stimulation for the treatment of headache attacks in patients with chronic migraine and medication-overuse headache [AAN abstract]. Neurology 82(suppl 10):P1.262
Metadata
Title
Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study
Authors
Licia Grazzi
Gabriella Egeo
Anne H. Calhoun
Candace K. McClure
Eric Liebler
Piero Barbanti
Publication date
01-12-2016
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-016-0684-z

Other articles of this Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue